Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Benning

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Clinical Investigator|April 1, 1993
Current therapy of systemic sclerosis (scleroderma)U Müller-Ladner, K Benning, B Lang
Immunitat Und Infektion|August 1, 1992
[Neonatal lupus erythematosus as an example of passively acquired autoimmunity]U Müller-Ladner, K Benning, E Röther, et al.
Zeitschrift Fur Rheumatologie|May 1, 1993
[Chronic recurrent polychondritis]K Benning, U Müller-Ladner, G Rauh, et al.
Medizinische Klinik (Munich, Germany : 1983)|November 15, 1995
[Differential internal medicine diagnosis of uveitis]K Benning, K C Le-Ruppert, U Müller-Ladner, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Clinical Investigator|April 1, 1993
Current therapy of systemic sclerosis (scleroderma)U Müller-Ladner, K Benning, B Lang
Immunitat Und Infektion|August 1, 1992
[Neonatal lupus erythematosus as an example of passively acquired autoimmunity]U Müller-Ladner, K Benning, E Röther, et al.
Zeitschrift Fur Rheumatologie|May 1, 1993
[Chronic recurrent polychondritis]K Benning, U Müller-Ladner, G Rauh, et al.
Medizinische Klinik (Munich, Germany : 1983)|November 15, 1995
[Differential internal medicine diagnosis of uveitis]K Benning, K C Le-Ruppert, U Müller-Ladner, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Pageof 1